TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $115 from $110 and keeps a Buy rating on the shares. The firm expects another quarterly outperformance when the company reports its 4Q results and issues its 2025 guidance. Cowen views the Street forecasts of $4.42B and $0.66 as conservative.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $115 from $95 at Piper Sandler
- Boston Scientific (BSX) Q4 Earnings Cheat Sheet
- Boston Scientific price target raised to $119 from $101 at Raymond James
- Boston Scientific price target raised to $111 from $86 at Barclays
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations